1Queen Mary Hospital Hong Kong, China [email protected]
2GSK Stevenage, United Kingdom
3GSK Durham, NC
Dr. Yuen reports having received research support from AbbVie, Assembly Biosciences, Arrowhead Pharmaceuticals, Bristol Myers Squibb, Dicerna, Gilead, Immunocore, and Roche and consulting fees from Merck Sharp and Dohme and Silverback. An updated disclosure form is posted with the full text of the article at NEJM.org. Since publication of his article, Dr. Yuen reports having received consulting fees and research support from Fujirebio, Spring Bank Pharmaceuticals, Sysmex, and Dicerna and consulting fees from Antios, ClearB, Finch, and Merck Sharp and Dohme. No further potential conflict of interest relevant to this letter was reported.
